Cayman Islands vs Turks and Caicos Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Cayman Islands
0.2%
in 2024
Turks and Caicos Islands
0.2%
in 2024
Cayman Islands rank
98th
Turks and Caicos Islands rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Cayman Islands
- Turks and Caicos Islands
How they compare
Cayman Islands currently reports 0.2% against 0.2% in Turks and Caicos Islands, a difference of 0.0%.
Across all 10 years both countries report, Turks and Caicos Islands has been ahead every year.
Cayman Islands ranks 98th and Turks and Caicos Islands ranks 98th of 246 countries.
Head to head by decade
| Decade | Cayman Islands | Turks and Caicos Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Cayman Islands or Turks and Caicos Islands?
- Cayman Islands, at 0.2% against 0.2% in Turks and Caicos Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Cayman Islands and Turks and Caicos Islands?
- 0.0%, with Cayman Islands ahead.
- How many years of comparable data are there for Cayman Islands and Turks and Caicos Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Cayman Islands and Turks and Caicos Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Cayman Islands ranks 98th and Turks and Caicos Islands ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.